JW Pharmaceutical's Rivarojet 2/10mg Tops Sales in Dyslipidemia Combination Drugs

JW Pharmaceutical's 'Rivarojet 2·10mg'
JW Pharmaceutical's 'Rivarojet 2·10mg'[Photo=JW Pharmaceutical]

JW Pharmaceutical's dyslipidemia treatment, Rivarojet, has demonstrated its market competitiveness through its efficacy and safety.
On June 16, JW Pharmaceutical announced that Rivarojet 2/10mg achieved the highest sales in the two-drug combination market (statin and ezetimibe) in April.
According to the market research firm Ubist, Rivarojet 2/10mg recorded sales of 8.8 billion won, capturing a market share of 6.59%, marking an increase from 8.4 billion won and a 6.32% market share in December of the previous year.
Rivarojet is the first domestic two-drug combination reformulation that combines the dyslipidemia treatment components pitavastatin and ezetimibe. It helps reduce low-density lipoprotein cholesterol (LDL-C) levels by inhibiting cholesterol production in the liver and absorption in the intestine.
Notably, it ranked first in sales across major healthcare institutions, including general hospitals and clinics, as well as in key medical departments such as neurology and endocrinology. In general hospitals, sales reached 4.5 billion won with an 8.02% market share, while in clinics, sales were 3.6 billion won with a 5.18% market share as of April.
This success is attributed to the LDL-C control effects and safety of the pitavastatin component, as well as the competitive edge of the original combination product.
In a recent interim analysis of the 'VICTORY Study,' which evaluated the long-term efficacy and safety of Rivarojet in 1,400 Koreans, the median LDL-C levels showed significant improvement, with no notable changes in patients' fasting plasma glucose (FPG) levels.
JW Pharmaceutical is enhancing its competitiveness in the dyslipidemia treatment sector by expanding its lineup of pitavastatin-based combination products, including the original single-agent Rivaro. Recently, it launched Rivarojet 1/10mg, which combines 1mg of pitavastatin and 10mg of ezetimibe, aimed at patients requiring low-dose statin therapy or additional LDL-C control after single-agent treatment. This is expected to provide a tailored option for patients who need dosage adjustments or are sensitive to medications.
A JW Pharmaceutical representative stated, "The clinical value of Rivarojet has been recognized in the medical field, and we will continue to provide evidence for patients requiring long-term LDL-C management."



* This article has been translated by AI.